Protection from vascular risk in diabetic hypertension

Diabetes mellitus is a metabolic disorder characterized by hyperglycemia and associated with a high incidence of complications affecting both the microvascular and the macrovascular systems. Macrovascular disease affects the coronary arteries, the cerebral vessels, and the large peripheral arteries of the lower extremities. Microangiopathy affects the kidneys, eyes, and nerves. Both forms of complication are major causes of death and disability in diabetes. The precise pathophysiology of these vascular complications is becoming better understood, but specific treatment and prevention remain complex.

[1]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[2]  A. Sjølie,et al.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes , 1998, The Lancet.

[3]  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[4]  T. Hostetter,et al.  Aldosterone is a major factor in the progression of renal disease. , 1997, Kidney international. Supplement.

[5]  M. Tuck,et al.  Hypertension and diabetes. , 1991, Seminars in nephrology.

[6]  M. Muntzel,et al.  Metformin attenuates salt-induced hypertension in spontaneously hypertensive rats. , 1999, Hypertension.

[7]  H. Chase,et al.  Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. , 1993, Annals of ophthalmology.

[8]  C. Godson,et al.  Protein kinases C: potential targets for intervention in diabetic nephropathy , 1998, Current opinion in nephrology and hypertension.

[9]  A. Mark,et al.  The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. , 1993, Hypertension.

[10]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[11]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[12]  S. A. Kumar,et al.  REVERSAL OF DIABETIC NEPHROPATHY IN HUMAN CADAVERIC KIDNEYS AFTER TRANSPLANTATION INTO NON-DIABETIC RECIPIENTS , 1983, The Lancet.

[13]  K. Manogue,et al.  Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. , 1988, Science.

[14]  T. Bek,et al.  24-h ambulatory blood pressure and retinopathy in normoalbuminuric IDDM patients , 1998, Diabetologia.

[15]  H. Tada,et al.  An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-β and protein kinase C activity in cultured human mesangial cells , 1998, Diabetologia.

[16]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[17]  A. Neil,et al.  A Prospective Population-Based Study of Microalbuminuria as a Predictor of Mortality in NIDDM , 1993, Diabetes Care.

[18]  B. Sumpio,et al.  Antiproliferative effect of elevated glucose in human microvascular endothelial cells , 1998, Journal of cellular biochemistry.

[19]  I. Laher,et al.  Insulin potentiates norepinephrine-induced vascular tone by activation of protein kinase C and tyrosine kinase. , 1994, Canadian journal of physiology and pharmacology.

[20]  L S Geiss,et al.  Surveillance for diabetes mellitus--United States, 1980-1989. , 1993, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[21]  K. Tracey,et al.  Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.

[22]  G. King,et al.  Protein Kinase C in Diabetic Renal Involvement, the Perspective of its Inhibition , 2000 .

[23]  D. Cattran,et al.  Impact of gender on the renal response to angiotensin II. , 1999, Kidney international.

[24]  D. Ganten,et al.  Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. , 1996, The British journal of ophthalmology.

[25]  H. Parving,et al.  Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. , 1998, Kidney international.

[26]  K. Ohnaka,et al.  Enhanced secretion of endothelin‐1 by elevated glucose levels from cultured bovine aortic endothelial cells , 1990, FEBS letters.

[27]  A. Krolewski,et al.  Gender-specific association of M235T polymorphism in angiotensinogen gene and diabetic nephropathy in NIDDM. , 1998, Hypertension.

[28]  H. Parving,et al.  Renal protection in diabetes: an emerging role for calcium antagonists , 1996, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[29]  P T de Jong,et al.  Angiotensin levels in the eye. , 1994, Investigative ophthalmology & visual science.

[30]  B. Hogan,et al.  Angiotensinogen gene null-mutant mice lack homeostatic regulation of glomerular filtration and tubular reabsorption. , 1998, Kidney international.

[31]  H. Yki-Järvinen,et al.  Serum total renin, an independent marker of the activity and severity of retinopathy in patients with IDDM , 1998, The British journal of ophthalmology.

[32]  A. Vinik,et al.  Progression of Diabetic Retionopathy after Pancreas Transplantation , 1990 .

[33]  G. Beck,et al.  Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. , 1996, The New England journal of medicine.

[34]  F. Cambien,et al.  Relationships Between Angiotensin I Converting Enzyme Gene Polymorphism, Plasma Levels, and Diabetic Retinal and Renal Complications , 1994, Diabetes.

[35]  M. Lishner,et al.  Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients , 1993, Annals of Internal Medicine.

[36]  J. Ferriss,et al.  Diabetic Control and the Renin‐Angiotensin System, Catecholamines, and Blood Pressure , 1985, Hypertension.

[37]  P. Brazy,et al.  Progressive renal disease: role of race and antihypertensive medications. , 1990, Kidney international.